<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879228</url>
  </required_header>
  <id_info>
    <org_study_id>818014</org_study_id>
    <nct_id>NCT01879228</nct_id>
  </id_info>
  <brief_title>Effect of Chronic Incretin-based Therapy in Cystic Fibrosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, diabetes has emerged as one of the most significant co-diseases that many&#xD;
      Cystic Fibrosis (CF) patients develop. Type 1 and Type 2 diabetes results when either the&#xD;
      body does not make enough insulin or the body does not respond correctly to this insulin.&#xD;
      Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar)&#xD;
      from the food we eat to the cells of the body for energy. While cystic fibrosis related&#xD;
      diabetes (CFRD) has many features similar to both Type 1 and Type 2 diabetes, it is very&#xD;
      different; therefore, treatment and care of CFRD is not the same.&#xD;
&#xD;
      The purpose of this research study is to examine and understand the various mechanisms that&#xD;
      contribute to CFRD and gain a better understanding of potential means to treat CFRD. The&#xD;
      primary objective is to determine effectiveness of chronic incretin-based therapy vs. placebo&#xD;
      on insulin secretion in CF patients with indeterminate glucose tolerance, impaired glucose&#xD;
      tolerance, or CFRD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insufficient incretin action has been associated with T2D. To study the possible link between&#xD;
      insufficient incretin action and impaired insulin secretion in CFRD as in T2D, the present&#xD;
      study will determine whether early intervention with incretin-based therapy using the DPP-4&#xD;
      inhibitor sitagliptin (Januvia®) to raise endogenous levels of the incretin&#xD;
      hormones--i.e.--glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrophic&#xD;
      polypeptide (GIP) for a 6-month period will improve insulin secretion in CF patients with&#xD;
      indeterminate glucose tolerance, impaired glucose tolerance or early CFRD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in second-phase insulin response derived from the glucose-potentiated arginine test as a measure of β-cell sensitivity to glucose at baseline and at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The key endpoint of interest will be the change in second phase insulin response derived from the Glucose-Potentiated Arginine (GPA) test. The GPA test will measure insulin (and other glucose controlling hormones) which will be a measure of pancreatic endocrine function in response to the injection of arginine. Arginine is a naturally occurring amino acid (substance) in the body. It will be given in the veins to make the pancreas secrete insulin. After the first injection of arginine, a glucose infusion will be started in order to raise the level of sugar in the blood to 230 mg/dl. Once the level is achieved, arginine will be injected again and blood samples are measured. After a 2 hour break, the glucose infusion will be started to achieve a blood sugar of 340 mg/dl and the arginine injection will be repeated. Comparison of responses at baseline and after 6 months of incretin-based therapy (Sitagliptin) or placebo will be performed using statistical methods.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet will be taken orally each morning for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of CF, defined by positive sweat test or CFTR mutation analysis&#xD;
             according to CFF diagnostic criteria&#xD;
&#xD;
          -  Age ≥ 18y on date of consent&#xD;
&#xD;
          -  Pancreatic insufficiency&#xD;
&#xD;
          -  Recent OGTT consistent with Indeterminate-GT, IGT, CFRD w/o fasting hyperglycemia, or&#xD;
             an established diagnosis of CFRD without fasting hyperglycemia&#xD;
&#xD;
          -  For female subjects, negative urine pregnancy test at enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of non-CF diabetes (i.e. T1D) or CFRD with fasting&#xD;
             hyperglycemia, (fasting glucose &gt; 126 mg/dL)&#xD;
&#xD;
          -  History of clinically symptomatic pancreatitis within last year,&#xD;
&#xD;
          -  Prior lung or liver transplant,&#xD;
&#xD;
          -  Severe CF liver disease, as defined by portal hypertension,&#xD;
&#xD;
          -  Fundoplication-related dumping syndrome,&#xD;
&#xD;
          -  Medical co-morbidities that are not CF-related or are unstable per investigator&#xD;
             opinion (i.e. history of bleeding disorders, immunodeficiency),&#xD;
&#xD;
          -  Acute illness or changes in therapy (including antibiotics) within 6 weeks prior to&#xD;
             enrollment,&#xD;
&#xD;
          -  Treatment with oral or intravenous corticosteroids within 6 weeks of enrollment,&#xD;
&#xD;
          -  Hemoglobin &lt;10g/dL, within 90 days of Visit 1 or at Screening,&#xD;
&#xD;
          -  Abnormal renal function, within 90 days of Visit 1 or at Screening; defined as&#xD;
             Creatinine clearance &lt; 50 mL/min (based on the Cockcroft-Gault formula) or potassium &gt;&#xD;
             5.5mEq/L on non-hemolyzed specimen,&#xD;
&#xD;
          -  A history of anaphylaxis, angioedema or Stevens-Johnson syndrome,&#xD;
&#xD;
          -  Inability to perform study specific procedures (MMTT, GPA),&#xD;
&#xD;
          -  Subjects, who in study team opinion, may be non-compliant with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Rickels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia and University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19194</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <disposition_first_submitted>December 14, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 14, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 21, 2020</disposition_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Michael R. Rickels, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01879228/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01879228/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

